-
STRIDE is a first step in addressing unmet needs in comorbid PAD and type 2 diabetes
CORRECTION: Subodh Verma, MD, PhD, FRCSC, and others explained how semaglutide can change the trajectory of disease in individuals with type 2 diabetes and peripheral artery disease.
-
REDEFINE trials advance combination treatment for weight management
Experts discussed findings from two phase 3 studies that evaluated the efficacy of combined treatment with an amylin analog and a glucagon-like peptide 1 (GLP-1) receptor agonist in inducing weight loss in individuals living with obesity or overweight.
-
Speakers will dispel myths about muscle and energy expenditure
Lara Dugas, PhD, MPH, and other panelists will examine the impact of common misconceptions and summarize new insights about the dynamics of muscle mass, energy expenditure, and individual metabolism.
-
Panel to explain why smarter is better in pediatric diabetes
Pediatric endocrinologist and physician-scientist Mustafa Tosur, MD, FAAP, will open a symposium on trending topics and smart solutions for diagnosing and managing diabetes in children, adolescents, and young adults.
-
Experts to present new approaches to lower triglycerides, pancreatitis risk
Panelists, including Savitha Subramanian, MD, will detail the latest therapies for severe hypertriglyceridemia, the genetics of hypertriglyceridemia, and the dynamics of hypertriglyceridemia-induced acute pancreatitis
-
PATHWEIGH demonstrates significant weight loss for primary care model
Speakers shared evidence of population-wide weight loss and improved use of weight-related treatment. Mark Gritz, PhD, said the goal was affordable care delivery that could be implemented broadly.
-
2025 Outstanding Educator in Diabetes Award honoree focuses on nutrition
Alison Evert, MS, RDN, CDCES, discussed three key components of diabetes nutrition therapy in her award lecture: research, recommendations, and real-world experiences.
-
Symposium features promise of non-peptide GLP-1 RAs and first report of phase 3 ACHIEVE-1
Julio Rosenstock, MD, shared data from ACHIEVE-1 that show orforglipron led to reductions in A1C and meaningful weight loss as monotherapy in drug-naïve type 2 diabetes with inadequate glycemic management.
-
Celebrity advocate promotes awareness for diabetes in session where ADA President, Health Care & Education touts multidisciplinary approach to care
Actor and diabetes advocate Anthony Anderson had a sit-down conversation with American Diabetes Association® (ADA) Chief Executive Officer Charles “Chuck” Henderson in which he told his own diabetes story during a Saturday session that included the ADA President, Health Care & Education Address.
-
Session will explore analytical tools and use of CGM data to deliver precision diabetes care
Artificial intelligence and machine learning are helping advance personalized medicine. Michael Snyder, PhD, will discuss how continuous glucose monitoring data is transforming diabetes subtyping and management.